<DOC>
	<DOC>NCT01653444</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and exploratory efficacy of GC1119 (recombinant human α-galactosidase A) for enzyme replacement therapy in Fabry disease patients.</brief_summary>
	<brief_title>Evaluate the Safety and Exploratory Efficacy of GC1119</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Subjects with a current diagnosis of Fabry's disease Plasma αgal activity of ≤ 1.5mnol/hr/ml and have a mutation in αgalactosidase A gene Males ≥ 16 years old Subjects capable of performing this clinical trial in an appropriate manner Informed consent form voluntarily signed by the subject(or his legally acceptable representative if the subject is under 20 years old) to participation in the study Agreement to contraception during the study period Serum creatinine &gt; 2.5mg/dl Subjects have a plan to kidney transplantation Subjects have undergone kidney transplantation Subjects are currently on dialysis Subjects have a clinically significant organic disease(cardiovascular, hepatic, pulmonary, neurologic, or renal disease)that in the opinion of the investigator would preclude participation in the trial Known lifethreatening hypersensitivity(anaphylactic reaction) to αgalactosidase Treatment with another investigational product within 30days from the administration of study drug dosing or plans to be treated with another investigational product during the study period Known hypersensitivity to any of the ingredients of study drug(including excipients) Subjects need the medication of prohibited drug Alcoholism or drug addiction</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>